Lacutamab is under clinical development by Innate Pharma and currently in Phase II for Transformed Mycosis Fungoides. According to GlobalData, Phase II drugs for Transformed Mycosis Fungoides does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Lacutamab LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lacutamab overview

Lacutamab (IPH-4102) is under development for the treatment of relapsed and refractory sezary syndrome (SS),cutaneous T-cell lymphomas such as transformed mycosis fungoides (TMF),and relapsed and refractory including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), follicular T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, adult T-cell leukemia/lymphoma (ATL), hepatosplenic T-cell lymphoma (HSTL), enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and aggressive NK-cell leukemia (ANKL). It was administered intravenously. The drug candidate is a cytotoxic antibody against KIR3DL2-expressing cancers.

Innate Pharma overview

Innate Pharma develops antibodies to treat cancer by harnessing the immune system. It offers Lumoxiti, a CD22-directed immunotoxin for the treatment of relapsed or refractory (r/r) hairy cell leukemia. The company is investigating Lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody for cutaneous T-cell lymphoma (CTCL), Monalizumab, an immune checkpoint inhibitor targeting solid tumors. Innate Pharma is also evaluating IPH5201, IPH5301, IPH6101, IPH6401, IPH6501 and IPH62 antibodies for the treatment of various of tumors. It works in partnership with Sanofi SA, AstraZeneca Plc and other biopharmaceutical companies to develop its products. Innate Pharma is headquartered in Marseille, Provence Alpes Cote d’Azur, France.

For a complete picture of Lacutamab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.